Introduction {#S1}
============

*Staphylococcus aureus* is a kind of facultative anaerobe pathogenic Gram-positive coccus with strong resistance and tolerance to harsh environments ([@B31]). At present, *S. aureus* has become a significant pathogen of nosocomial infections, such as deep-seated skin and soft tissue infections (SSTI), endocarditis, and other life-threatening severe infections ([@B17]). In recent years, with the widespread use of antibiotics, the emergence of multidrug-resistant (MDR) *S. aureus* has become a major concern ([@B13]). In addition, the lack of effective clinical treatments against MDR *S. aureus* has rekindled the interest of clinicians in fosfomycin. It is an antimicrobial agent that was discovered in *Streptomyces* sp. It exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria by inhibiting the peptidoglycan synthesis pathway, which is essential for the synthesis of the cell walls ([@B23]). However, the number of fosfomycin-resistant *S. aureus* strains is increasing rapidly ([@B9]).

Several mechanisms of fosfomycin resistance have been proposed, including the plasmid-encoded fosfomycin-modifying enzymes (FosA, FosB, FosC, FosD, and FosX) and the acquisition of chromosomal mutations ([@B20]; [@B16]; [@B24]). Mutations in the MurA target enzyme and transporters (GlpT and UhpT) have been shown to be responsible for fosfomycin resistance ([@B18]). Additionally, the overexpression of target enzymes, MurA and Tet38 efflux pump, also contributes to fosfomycin resistance in *S. aureus* ([@B28]). Notably, there are no reports yet suggesting that fosfomycin can stimulate the expression of the efflux pump gene and mediate drug resistance. However, a few studies on *S. aureus* have described the drug sensitivity and resistance mechanism of fosfomycin in *S. aureus*, although they are not fully understood.

In the present study, we focus on the mutations of the target enzyme MurA, which catalyzes the initial step in the biosynthesis of peptidoglycan and transporters (GlpT and UhpT), as well as the overexpression of *murA* and *tet38* efflux pump in 11 fosfomycin-resistant *S. aureus.* In addition, a strong correlation was established between fosfomycin resistance and efflux pump gene *tet38* overexpression that has not been reported previously. The results of quantitative real-time PCR (qRT-PCR) indicated that the Tet38 efflux pump plays a vital role in fosfomycin resistance by pumping out the drug.

Materials and Methods {#S2}
=====================

Bacterial Strains {#S2.SS1}
-----------------

In 2018, a total of 200 *S. aureus* isolates were obtained from the First Affiliated Hospital of Wenzhou Medical University, a comprehensive teaching hospital in China. The bacteria were identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS; BioMérieux, Lyons, France). *S. aureus* ATCC 29213 (American Type Tissue Culture Collection, Manassas, VA, United States) was used as an endogenous control strain in antimicrobial susceptibility testing experiments. The study and consent procedure were approved by the Ethics Committee of the hospital.

Antimicrobial Susceptibility Testing {#S2.SS2}
------------------------------------

The minimum inhibitory concentration (MIC) of fosfomycin for each clinical strain was determined using the agar dilution method, wherein the media were supplemented with glucose-6-phosphate (25 mg/L), according to the recommendations of the [@B5] ([@B29]). The data were interpreted according to the European Committee on Antimicrobial Susceptibility Testing criteria (available at <http://www.eucast.org/clinical_breakpoints/>) (susceptible, ≤32 mg/L; resistant, ≥64 mg/L), and the fosfomycin-resistant isolates were selected for further investigation. In addition, the MICs of fosfomycin-resistant *S. aureus* to other classes of antibiotics, including oxacillin, erythromycin, ciprofloxacin, levofloxacin, gentamicin, rifampicin, linezolid, vancomycin, and teicoplanin, were detected using the broth microdilution method.

Detection of Fosfomycin-Resistant Genes {#S2.SS3}
---------------------------------------

The DNA of fosfomycin-resistant and fosfomycin-susceptible *S. aureus* isolates was extracted using a Biospin Bacterial Genomic DNA Extraction Kit (Bioflux, Tokyo, Japan) and was utilized as the template for PCR amplification of the *fosA*, *fosB*, *fosC*, *fosD*, *fosX*, *glpT*, *uhpT*, *murA*, and *tet38* genes; the primers are listed in [Table 1](#T1){ref-type="table"}. The PCR products were sequenced by Beijing Genomics Institute Technology Co., Ltd. (Shanghai, China), and the sequences were aligned by BLAST on the NCBI platform^[1](#footnote1){ref-type="fn"}^. The PCR products of *uhpT*, *glpT*, and *murA* were sequenced to scan for mutations.

###### 

Primers used in this study.

  Gene                  Primer sequences (5′→3′)       Product size (bp)   References
  --------------------- ------------------------------ ------------------- -----------------
  **PCR primers**                                                          
  *fosA*                F:GCTGCACGCCCGCTGGAATA         217                 [@B4]
                        R:CGACGCCCCCTCGCTTTTGT                             
  *fosB*                F:CAGAGATATTTTAGGGGCTGACA      312                 [@B4]
                        R:CTCAATCTATCTTCTAAACTTCCTG                        
  *fosC*                F:GGGTTACATGCCCTTGCTCA         354                 [@B4]
                        R:AACCCGCACAACGACAGATG                             
  *fosD*                F: AACTCTAACTTGTGTCCGTCAG      220                 [@B16]
                        R: GTGGCTTATGGGTTGCGTTA                            
  *fosX*                F: ATGATCAGTCATATGACATTTATCG   243                 [@B35]
                        R: ATTTAGCCCCTTGTCGATAACG                          
  *murA*                F:GCCCTTGAAAGAATGGTTCGT        1600\*              NC_002745.2\*\*
                        R:GTTACAATACTCGACGCAGGT                            
  *glpT*                F:TGAATAAAACAGCAGGGCAA         1699\*              NC_002745.2\*\*
                        R:CACAGCTAGTATGTATAACGAC                           
  *uhpT*                F:TGTGTTTATGTTCAGTATTTTGGA     1571\*              NC_002745.2\*\*
                        R:TCTTTCATCTCTTCACGCAC                             
  *tet38*               F:GCGGATACAACAGCGAGTGA         1353                [@B27]
                        R:TCGACGCACCTAATGGGAAT                             
  **qRT-PCR primers**                                                      
  *gmk*                 F:ACTAGGGATGCGTTTGAAGC         122                 [@B3]
                        R:TCATGACCTTCGTCCATTGT                             
  *tet38*               F:TGACAGGTGTGGCTATTGGT         112                 [@B3]
                        R:TTGCCTGGGAAATTTAATGC                             
  *murA*                F:TGTGCACCTTGCAATTGACT         102                 [@B11]
                        R:CCGTTTTATGCATGTTGCAG                             

\*

PCR product including surrounding sequences adjacent to the target gene.

\*\*

GenBank-EMBL-DDBL accession number.

Fosfomycin Treatment and Total RNA Isolation {#S2.SS4}
--------------------------------------------

Actively growing *S. aureus* specimens were treated with increasing concentrations of fosfomycin (1/8 MIC, 1/4 MIC, and 1/2 MIC) for 2 h, after which the cells were harvested, and total RNA was extracted using a Bacterial RNA Miniprep Kit (Biomiga, Shanghai, China) according to the manufacturer's instructions. Then, 1000 ng RNA was used as the template for reverse transcription using a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, United States) to obtain cDNA.

Quantitative Real-Time PCR (qRT-PCR) {#S2.SS5}
------------------------------------

qPCR was performed on a CFX-96 Touch^TM^ Real-Time PCR system (Bio-Rad, Hercules, CA, United States) using TB Green Premix Ex Taq II (Tli RNase H Plus) (2×) (Takara, Japan), specific primers ([Table 1](#T1){ref-type="table"}), and 100 ng cDNA as the template. Cycling conditions were as follows: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 20 s. A melting curve was performed after each run (raising the temperature by 0.5°C/s, from 65 to 95°C). Each sample was run in triplicate, and the means of the Ct values were used for analysis. The relative expression levels of *tet38* and *murA* genes were normalized to the *gmk* reference gene ([@B3]). The quantification of the target genes was analyzed using the comparative threshold cycle 2^--ΔΔ*Ct*^ method. All experiments were repeated in triplicate independently. The relative expression of the mRNA of the target gene was normalized to that of *S. aureus* ATCC 29213.

Multilocus Sequence Typing (MLST) {#S2.SS6}
---------------------------------

Isolates were screened using a previously described method to detect the following seven housekeeping genes: carbamate kinase (*arcC*), shikimate dehydrogenase (*aroE*), glycerol kinase (*glp*), guanylate kinase (*gmk*), phosphate acetyltransferase (*pta*), triosephosphate isomerase (*tpi*), and acetyl coenzyme A acetyltransferase (*yqiL*) ([@B8]). The sequences of the PCR products were compared with those available from the MLST website^[2](#footnote2){ref-type="fn"}^ for *S. aureus*. Also, the allelic number was determined for each sequence.

Planktonic Growth Assay {#S2.SS7}
-----------------------

The planktonic growth rates of 8 *tet38*-overexpressed *S. aureus* isolates were determined as described previously ([@B32]), with some modifications. Briefly, 8 *tet38*-overexpressed isolates and ATCC 29213 standard cell suspensions were prepared by adjusting the turbidity of suspension to 0.5 McFarland standard in sterile saline. Then, 200 μL of each suspension was inoculated in 20 mL sterile LB broth containing fosfomycin in 0, 1/8 MIC, 1/4 MIC, and 1/2 MIC, respectively, for growth at 37°C and 180 rpm for 24 h. The growth rate of the planktonic bacteria was determined by measuring the optical density (OD) of the suspension in each well of the 96-well plate at 600 nm at 2-h intervals for 24 h using a microtiter plate reader (BioTek, United States). The growth curve was generated in triplicate for each experiment. ATCC 29213 served as the control strain.

Statistical Analysis {#S2.SS8}
--------------------

The relative expression of *murA* and *tet38* was compared using Student's *t*-test, and *P-*value \< 0.05 was considered to be statistically significant.

Results {#S3}
=======

Susceptibility to Fosfomycin and Other Types of Antibiotics {#S3.SS1}
-----------------------------------------------------------

The susceptibility to fosfomycin of 200 *S. aureus* isolates was determined by the agar dilution method using glucose-6-phosphate (25 mg/L). The results showed that 5.5% (11/200) of the isolates were resistant to fosfomycin. Also, resistance to other antibiotics was determined ([Table 2](#T2){ref-type="table"}); 81.8% (9/11) of the isolates displayed resistance to erythromycin, while 72.7% (8/11) belonged to MDR *S. aureus*.

###### 

Characteristics and resistance spectrum of fosfomycin-resistant *S. aureus* strains.

  Isolates   ST type   FOM        OXA        ERY     CIP        LVX     GEN       RIF       LNZ   VAN   TEC
  ---------- --------- ---------- ---------- ------- ---------- ------- --------- --------- ----- ----- -----
  JP3187     5         256^*R*^   \>128^R^   32^R^   \>256^R^   32^R^   4         \<0.03    2     2     4
  JP3189     4539      64^R^      \>128^R^   64^R^   64^R^      32^R^   16^R^     \>16^R^   1     1     4
  JP3212     5         256^R^     \>128^R^   64^R^   128^R^     32^R^   4         \<0.03    2     2     8
  JP3235     5708      64^R^      \>128^R^   1       128^R^     32^R^   64^R^     \>16^R^   2     1     4
  JP3244     7         128^R^     0.5        64^R^   0.25       0.25    \<0.125   \<0.03    2     1     0.5
  JP3505     4739      512^R^     0.5        1       2          1       \<0.125   \<0.03    4     2     0.5
  JP3535     5         64^R^      \>128^R^   16^R^   128^R^     16^R^   0.25      \<0.03    4     1     2
  JP3539     59        64^R^      8^R^       64^R^   0.5        0.25    0.25      \<0.03    4     2     1
  JP3589     1         64^R^      0.25       64^R^   2          1       2         \<0.03    2     2     1
  JP3592     239       256^R^     \>128^R^   64^R^   128^R^     64^R^   \<0.125   \>8^R^    4     1     1
  JP3600     965       64^R^      0.5        64^R^   4^R^       1       0.5       \<0.03    2     2     2

FOM, fosfomycin; OXA, oxacillin; ERY, erythromycin; CIP, ciprofloxacin; LVX, levofloxacin; GEN, gentamicin; RIF, rifampicin; LNZ, linezolid; VAN, vancomycin; TEC, teicoplanin. Superscript "R" indicates resistance.

Molecular Mechanisms of Fosfomycin-Resistant Isolates {#S3.SS2}
-----------------------------------------------------

Strains carrying the *fosA*, *fosB*, *fosC*, *fosD*, or *fosX* gene were not found in the current study ([Table 3](#T3){ref-type="table"}). Based on the classification method of [@B10] we named the sense mutations as TypeA, TypeB, and TypeC according to the amino acid sequence, and the nonsense mutations were named as TypeI, TypeII, and TypeIII; the subscripts represent different genes ([@B10]). Three distinct mutations were detected in the *uhpT* gene of the 11 fosfomycin-resistant *S. aureus* isolates and the corresponding sensitive strains. Mutation TypeA*~*uhpT*~*, found in JP3212, resulted in an amino acid substitution at position 457 (Leu457Val) of UhpT. Conversely, the other two mutations (TypeI--II*~*uhpT*~*), which resulted in distinct amino acid substitutions within the UhpT protein, were identified in fosfomycin-sensitive isolates, although one mutation (TypeII*~*uhpT*~*) was also found in fosfomycin-resistant *S. aureus* ([Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}).

###### 

Characteristics and amino acid substitutions in fosfomycin-resistant and fosfomycin-sensitive *S. aureus.*

  Strains   Type   *tet38*   *fos*   Amino acid substitution                                                                        
  --------- ------ --------- ------- ------------------------- ---- ---- ---- ------------------ ---------------------------------- ----------------------------------
  JP3187    R      \+        --      --                        --   --   --   None               TypeA*~*glpT*~*                    TypeI*~*murA*~*
  JP3189    R      \+        --      --                        --   --   --   None               None                               TypeC*~*murA*~*
  JP3212    R      \+        --      --                        --   --   --   TypeA*~*uhpT*~*    None                               TypeI*~*murA*~*
  JP3235    R      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~* TypeC*~*murA*~*
  JP3244    R      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~* TypeC*~*murA*~*
  JP3505    R      \+        --      --                        --   --   --   None               TypeI*~*glpT*~*                    TypeA*~*murA*~* TypeI*~*murA*~*
  JP3535    R      \+        --      --                        --   --   --   None               TypeI*~*glpT*~* TypeB*~*glpT*~*    TypeI*~*murA*~*
  JP3539    R      \+        --      --                        --   --   --   None               TypeA*~*glpT*~* TypeI*~*glpT*~*    TypeI*~*murA*~* TypeII*~*murA*~*
  JP3589    R      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~* TypeB*~*murA*~*
  JP3592    R      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~* TypeC*~*murA*~*
  JP3600    R      \+        --      --                        --   --   --   TypeII*~*uhpT*~*   TypeI*~*glpT*~*                    TypeI*~*murA*~*
  JP3200    S      \+        --      --                        --   --   --   None               None                               None
  JP3203    S      \+        --      --                        --   --   --   TypeI*~*uhpT*~*    None                               None
  JP3277    S                --      --                        --   --   --   None               None                               None
  JP3230    S      \+        --      --                        --   --   --   None               None                               None
  JP3240    S      \+        --      --                        --   --   --   TypeII*~*uhpT*~*   TypeI*~*glpT*~* TypeII*~*glpT*~*   None
  JP3245    S      \+        --      --                        --   --   --   None               None                               None
  JP3502    S      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~* TypeII*~*murA*~*
  JP3512    S      \+        --      --                        --   --   --   None               None                               None
  JP3518    S      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~*
  JP3520    S      \+        --      --                        --   --   --   None               TypeI*~*glpT*~*                    TypeI*~*murA*~*
  JP3522    S      \+        --      --                        --   --   --   None               None                               TypeI*~*murA*~*
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![Types and positions of mutations in *uhpT*, *glpT*, and *murA* genes. TypeA*~*uhpT*~*: T1369 G; TypeI*~*uhpT*~*: G1364A; TypeII*~*uhpT*~*: T1368G. TypeA~*glp*~*~*T*~*: C299T; TypeB~*glp*~*~*T*~*: G1064A; TypeI~*glp*~*~*T*~*: G583A; TypeII~*glp*~*~*T*~*: T829G. TypeA*~*murA*~*: G187A; TypeB*~*murA*~*: G349T; TypeC*~*murA*~*: G770A; TypeI*~*murA*~*: C371G; and TypeII*~*murA*~*: A873T.](fmicb-11-01290-g001){#F1}

Moreover, four different mutations were detected in the *glpT* gene (TypeA--B*~*glpT*~* and TypeI--II*~*glpT*~*). Notably, TypeB*~*glpT*~*, found in the fosfomycin-resistant isolates JP3535, produced a premature stop codon within the *glpT* coding sequence at position 355 (Trp335Ter), thereby resulting in truncated proteins. In addition, TypeII*~*glpT*~* was detected only in the fosfomycin-sensitive isolates ([Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}).

Of the 11 fosfomycin-resistant isolates, 6 contained one of the three different mutations (TypeA--C*~*murA*~*) in the *murA* gene. TypeA--C*~*murA*~*, which resulted in distinct amino acid substitutions within the MurA protein at positions 63 (Ala63Thr), 117 (Gly117Trp), and 257 (Gly257Asp), could only be found in fosfomycin-resistant isolates, and two mutations (TypeI--II*~*murA*~*) could be found in both fosfomycin-resistant and fosfomycin-susceptible *S. aureus* ([Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). Moreover, only one sense mutation was present in each fosfomycin-resistant *S. aureus* isolate.

Expression Analysis of *murA* and *tet38* {#S3.SS3}
-----------------------------------------

qRT-PCR revealed significant differences in the expression of *murA* between resistant and susceptible groups of *S. aureus* as compared with *S. aureus* ATCC 29213 (*P* \< 0.05) ([Table 4](#T4){ref-type="table"}). The data showed that the average expression level of *murA* gene decreased by 0.7-fold in fosfomycin-resistant and fosfomycin-susceptible *S. aureus* isolates. In addition, compared with the fosfomycin-susceptible *S. aureus*, the expression of *murA* in the resistance isolates was not significantly higher.

###### 

Relative expression of target enzyme gene *murA* and efflux pump gene *tet38* in fosfomycin-susceptible and fosfomycin-resistant *S. aureus*.

  Strains   Relative expression level of *murA*^a^ (mean ± SD)   Relative expression level of *tet38*^a^ (mean ± SD)
  --------- ---------------------------------------------------- -----------------------------------------------------
  S1        0.77 ± 0.15                                          0.77 ± 0.13
  S2        1.45 ± 0.10                                          1.48 ± 1.02
  S3        0.40 ± 0.05                                          0.71 ± 0.21
  S4        0.48 ± 0.01                                          1.55 ± 0.33
  S5        0.48 ± 0.06                                          0.98 ± 0.35
  JP3187    0.75 ± 0.09                                          1.71 ± 0.93
  JP3189    0.35 ± 0.01                                          0.71 ± 0.25
  JP3212    0.47 ± 0.01                                          **21.6 ± 5.75**
  JP3235    1.47 ± 0.14                                          0.92 ± 0.34
  JP3244    0.21 ± 0.04                                          1.24 ± 0.15
  JP3505    0.23 ± 0.04                                          **2.65 ± 1.04**
  JP3535    0.34 ± 0.03                                          **2.74 ± 0.37**
  JP3539    0.39 ± 0.05                                          1.71 ± 0.48
  JP3589    0.42 ± 0.08                                          0.54 ± 0.23
  JP3592    0.40 ± 0.07                                          **143.36 ± 2.05**
  JP3600    1.52 ± 0.23                                          **24.59 ± 0.17**

S1--S5 represent the 5 fosfomycin-susceptible

S. aureus

strains. ATCC 29213 served as the control strain.

a

The relative gene expression with more than 2-fold change compared with ATCC 29213 after fosfomycin induction is shown in bold.

However, the results ([Table 4](#T4){ref-type="table"}) indicated that compared with that in ATCC29213 and susceptible isolates, the expression level of efflux pump gene *tet38* in JP3212, JP3535, JP359, and JP3600 was elevated. Notably, the level of the *tet38* gene in JP3212, JP3535, JP3592, and JP3600 was altered markedly (21. 60-, 2. 74-, 143. 36-, and 24.59-fold) as compared with that in ATCC29213 ([Table 4](#T4){ref-type="table"}).

Exposure to Fosfomycin Resulted in Increased Expression of *tet38* Efflux Pump Genes Among Some Resistant Isolates {#S3.SS4}
------------------------------------------------------------------------------------------------------------------

The expression of *tet38* in the presence of increasing amounts of fosfomycin with 0, 1/8 MIC, 1/4 MIC, and 1/2 MIC concentrations was determined by qRT-PCR. Notably, the expression of the *tet38* gene in JP3187, JP3212, JP3244, JP3505 JP3535, JP3539, P3589, JP3592, and ATCC 29213 was upregulated with the increase in fosfomycin concentration as compared with the 0 MIC strains ([Figure 2](#F2){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). Also, 4.63-fold and 6.42-fold increases were noted in the expression of *tet38* in JP3505 cells treated with 1/8 MIC (64 mg/L) and 1/4 MIC (128 mg/L) fosfomycin, respectively, as compared with that in cells that were not treated with fosfomycin ([Table 5](#T5){ref-type="table"}). A further 8.46-fold increase was observed in those treated with 1/2 MIC (256 mg/L) fosfomycin.

###### 

Relative expression of efflux pump gene *tet38* in fosfomycin-resistant *S. aureus* exposed to different concentrations of fosfomycin.

  Strains   The relative expression level of *tet38*^a^ (mean ± SD)                                           
  --------- --------------------------------------------------------- ------------------- ------------------- ------------------
  JP3187    0.250.09                                                  0.320.08            **0.77 ± 0.10**     **4.64 ± 0.25**
  JP3189    0.380.08                                                  0.320.01            0.430.07            0.320.13
  JP3212    20.320.10                                                 21.890.69           22.220.56           23.020.8
  JP3235    0.530.12                                                  0.360.08            0.330.03            0.370.06
  JP3244    0.350.06                                                  **0.81 ± 0.20**     **0.83 ± 0.01**     0.680.03
  JP3505    2.270.91                                                   **10.51 ± 0.38**    **14.57 ± 2.12**   **19.21 ± 1.65**
  JP3535    2.500.12                                                  3.820.12            3.950.14            3.340.17
  JP3539    1.670.45                                                  2.400.08            **3.60 ± 0.08**     **4.60 ± 0.14**
  JP3589    0.270.02                                                  **0.57 ± 0.06**     **1.13 ± 0.14**     0.510.01
  JP3592    140.270.05                                                140.480.30          140.650.23          141.470.36
  JP3600    20.580.20                                                 20.620.04           20.470.08           20.930.72

a

The relative gene expression with more than 2-fold change compared with 0 MIC after fosfomycin induction is shown in bold.

![The relative expression of efflux pump gene *tet38* in fosfomycin-resistant *S. aureus* exposed to 0, 1/8 MIC, 1/4 MIC, and 1/2 MIC concentrations. Bars indicate the mean values, and asterisks denote the significant difference of expression (*P* \< 0.05).](fmicb-11-01290-g002){#F2}

Molecular Typing {#S3.SS5}
----------------

The 11 fosfomycin-resistant *S. aureus* specimens were categorized into 9 STs ([Table 2](#T2){ref-type="table"}): ST1 (*n* = 1), ST5 (*n* = 3), ST59 (*n* = 1), ST7 (*n* = 1), ST239 (*n* = 1), ST965 (*n* = 1), ST4539 (*n* = 1), ST4739 (*n* = 1), and a new ST that was found in the current study (ST 5708) (*n* = 1).

Growth Rate {#S3.SS6}
-----------

In order to gain quantitative insight into the fitness cost imposed by *tet38*-overexpressed isolates, the growth curves of 8 *tet38*-overexpressed *S. aureus* were recorded. We identified a fitness cost after fosfomycin induction. The growth of 8 *tet38*-overexpression strains was inhibited in LB at a subinhibitory concentration of fosfomycin ([Figure 3](#F3){ref-type="fig"}).

![Growth curves at different fosfomycin concentrations in *tet38*-overexpression *S. aureus*. The values shown are the average of three independent experiments. Different colors of lines represent different concentrations of fosfomycin. **(A)** Growth of control strain ATCC 29213. **(B--I)** Growth of 8 *tet38*-overexpression isolates.](fmicb-11-01290-g003){#F3}

Discussion {#S4}
==========

Due to the unique mechanisms of action, fosfomycin exhibits significant antimicrobial activity against a broad spectrum of pathogens, including *S. aureus* ([@B14]). A review described that the susceptibility of *S. aureus* to fosfomycin ranged from 33.2% to 100% in the nine available studies \[odds ratio (OD) = 91.7%, 95% confidence interval (CI): 88.7--94.9%\] ([@B30]). In the current study, the susceptibility rate of fosfomycin in *S. aureus* was 94.5% (189/200). However, the prevalence of fosfomycin resistance in clinical isolates of *S. aureus* has been reported with increasing frequency in many areas ([@B7]; [@B19]; [@B22]).

The resistance mechanism of fosfomycin in Gram-negative bacteria has been widely reported; also, in a previous study, we reported the resistance of fosfomycin in ESBL-producing *Escherichia coli* ([@B1]). Fosfomycin enters the cell via two transporters, GlpT and UhpT, and mutations or insertions in *glpT* and/or *uhpT* genes result in the loss of function ([@B25]). According to the study by [@B2], *glpT* inactivation played an essential role in the resistance to fosfomycin in *Pseudomonas aeruginosa* ([@B2]). The *murA* gene is also closely related to fosfomycin resistance ([@B25]; [@B6]). In addition, fosfomycin activity can be inhibited via the catalytic activity of FosA, FosB, and FosC, respectively ([@B12]; [@B15]).

Among Gram-positive bacteria, the resistance mechanism of fosfomycin is rarely reported. In the current study, none of the resistant strains carried the *fosA*, *fosB*, *fosC*, *fosD*, or *fosX* gene, indicating that these genes might not be the primary factors mediating the resistance of *S. aureus* against fosfomycin. Other studies have shown that the prevalence of fosfomycin resistance genes (*fosA*, *fosB*, and *fosC*) was not the predominant factor contributing to resistance in *S. aureus* ([@B34]). In addition, a total of 12 mutations were found in 11 strains of fosfomycin-resistant *S. aureus* by sequencing analysis. Of these, 3 were detected in *uhpT*, and TypeA*~*uhpT*~* was carried only by fosfomycin-resistant strain JP3212, while TypeI*~*uhpT*~* and TypeII*~*uhpT*~* were found in both fosfomycin-resistant and fosfomycin-sensitive strains, which likely did not contribute to fosfomycin resistance. Within the *glpT* gene of 11 drug-resistant strains, 2 mutations TypeA--B*~*glpT*~* were observed only in the drug-resistant strains. On the other hand, mutation TypeI*~*glpT*~* was widely detected in both drug-resistant and susceptible strains. Intriguingly, TypeB*~*glpT*~*, which generated a stop codon (TA~1064~G) at position 335 ([Figure 1](#F1){ref-type="fig"}), was harbored in JP3535. Also, we found a mutation (TypeII*~*glpT*~*) merely in the fosfomycin-sensitive strains. Of the five *murA* gene mutations found in the drug-resistant strains, TypeI*~*murA*~* and TypeII*~*murA*~* could also be found in susceptible strains, and the remaining three mutations (TypeA--C*~*murA*~*) were found only in drug-resistant strains (TypeA*~*murA*~*: JP3505; TypeB*~*murA*~*: JP3589; TypeC*~*murA*~*: JP3189, JP3235, JP3244; JP3592). In addition, TypeI*~*murA*~* was also found in fosfomycin-resistant strains (10/11). Among the above mutations, four mutation sites, TypeA*~*glpT*~*, TypeB*~*glpT*~*, TypeC*~*murA*~*, and TypeII*~*murA*~*, were consistent with those reported ([@B10]). We also found that the frequency of *murA* mutation in *S. aureus* was high, which might play a major role in mediating fosfomycin resistance, which needs an in-depth investigation.

Although several studies have mentioned that the overexpression of the *murA* gene can greatly increase the MICs of fosfomycin, the difference in *murA* expression between fosfomycin-sensitive and fosfomycin-resistant *S. aureus* has not been reported ([@B12]; [@B21]). In the current study, the results of qRT-PCR revealed a significant difference between the fosfomycin-resistant and fosfomycin-susceptible *S. aureus* with respect to the expression of *murA* as compared with that of *S. aureus* ATCC 29213. However, statistical differences could not be detected between two types of strains ([Table 4](#T4){ref-type="table"}), indicating that the overexpression of target gene *murA* has no role in conferring fosfomycin resistance in the strains identified in this study. Interestingly, some resistant strains showed a downward trend in the expression of *murA*, suggesting that the role of the *murA* gene in fosfomycin needs to be studied further.

Recent studies have shown that the *tet38* gene exerts a specific effect on fosfomycin resistance. According to the study by Truong-Bolduc, the overexpression of *tet38* resulted in a fourfold increase in the MIC of fosfomycin compared with that of the parent strain ([@B28]). The results of the current study showed that the expression of the *tet38* efflux pump gene in fosfomycin-resistant strains JP3212, JP3535, JP3592, and JP3600 was significantly higher than that in the control strain ATCC29213 and the susceptible strains (*P* = 0.007, *P* = 0.002, *P* \< 0.001, *P* \< 0.001, respectively). Furthermore, under the treatment of 0, 1/8 MIC, 1/4 MIC, and 1/2 MIC with fosfomycin, we found that the expression of efflux pump gene *tet38* was upregulated in most resistant isolates, even in the reference strain ATCC 29213. Although nonsense mutation was detected in *uhpT*, *glpT*, and *murA* genes, the level of *tet38* in JP3600 was high even without the drug, which might explain the resistance to fosfomycin. This phenomenon suggests that the *tet38* efflux pump plays a critical role in mediating fosfomycin resistance. Reportedly, abscess and other factors can promote the expression of *tet38* ([@B3]), and the current study has shown that the stimulation of the drug also enhances the expression of the efflux pump, albeit the specific mechanism remains to be studied further. Moreover, the overexpression of *tet38* can also lead to changes in the cost of bacterial fitness. Some studies have demonstrated that the global regulator MgrA functions as a direct regulator of *tetR21*, which is a TetR-like regulator of the *tet38* efflux pump gene. TetR21 acts as a repressor of tet38 expression and may also regulate the expression of other bacterial resistance determinants ([@B27], [@B26]). We speculated that the high expression of the *tet38* gene in *S. aureus* might be related to the regulation of TetR-like regulator TetR21 and the global regulator MgrA. We will also continue to focus on these phenomena in other bacteria in future studies.

MLST analyses designated three fosfomycin-resistant *S. aureus* isolated to ST5. Combined with drug sensitivity, we found that the ST5 resistant strains were resistant to at least five antibiotics. Among 11 fosfomycin-resistant strains, 72.7% were MDR strains, and further follow-up treatment was essential. [@B33] reported that ST5 and ST239 strains were usually resistant to fosfomycin and constituted the predominant HA-MRSA clones in China. The new sequence type found in the resistant strain has been submitted to the repository (see text footnote 2).

Conclusion {#S5}
==========

A total of 11 fosfomycin-resistant strains were screened out from 200 *S. aureus* isolates, and the mechanism was explored. Our findings indicated that *fosA*, *fosB*, *fosC, fosD*, and *fosX* genes might not be the major resistant mechanism of *S. aureus* to fosfomycin. The mutations within the *glpT*, *uhpT*, and *murA* genes might play a critical role in conferring fosfomycin resistance. However, the role of overexpression of *murA* in fosfomycin resistance needs to be discussed further in *S. aureus*. Also, the phenomenon of overexpression in the *tet38* gene under a subinhibitory concentration of fosfomycin needs to be investigated further.
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